Status:
COMPLETED
Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine-Related Disorders
Opioid-Related Disorders
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Fluoxetine, a medication that is currently used to treat depression and anxiety disorders, may...
Detailed Description
Individuals addicted to cocaine often experience feelings of restlessness, irritability, anxiety, and paranoia. Reducing cocaine use can lead to depression. In an attempt to alleviate the depressive s...
Eligibility Criteria
Inclusion
- Currently dependent on opioids
- Currently dependent on cocaine
- Eligible to receive methadone maintenance treatment
Exclusion
- Current significant medical or psychiatric illness
- Current use of a specific serotonin reuptake inhibitor (SSRI)
- History of allergy to SSRI medications
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00142779
Start Date
April 1 2001
End Date
March 1 2006
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21224